NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
Clinical Trials
25 trialsNCT04100187 2022-12-01
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
Phase 1 Unknown
NCT04684472 2022-09-26
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Sichuan University
Phase 1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown
NCT04709458 2022-05-03
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
Phase 1 Unknown
NCT04014894 2021-11-12
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT03798509 2021-08-31
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Hrain Biotechnology Co., Ltd.
Phase 1 Unknown
NCT02546739 2021-01-26
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT03271515 2021-01-20
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT03836690 2019-10-25
ToTem
University College, London
Phase 1 Unknown
NCT02799550 2019-02-25
Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1 Unknown
NCT03685786 2018-12-07
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT02822326 2017-09-11
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
Guangdong Provincial People's Hospital
Phase 1 Unknown
NCT02656147 2017-09-05
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT01793025 2017-08-30
ATAC-AML-01
Maisonneuve-Rosemont Hospital
Phase 1 Unknown
NCT03114670 2017-06-14
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown
NCT03121625 2017-04-25
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1 Unknown
NCT01280786 2014-02-03
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Synta Pharmaceuticals Corp.
Phase 1 Unknown
NCT00004858 2013-09-20
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00544999 2013-09-17
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00003073 2010-03-23
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00004086 2009-06-09
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00462189 2007-04-18
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Cambridge Antibody Technology
Phase 1 Unknown
NCT00457860 2007-04-17
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Cambridge Antibody Technology
Phase 1 Unknown